AllSci News
Pfizer terminates Phase I trial of Seagen-acquired PD-L1 targeted TLR7 agonist ISAC
Pfizer has terminated a Phase 1 clinical trial evaluating PF-08046037 (also known as SGN-PDL1iT), an immunostimulatory antibody conjugate targeting PD-L1,...
Cumberland Pharmaceuticals divests branded portfolio to Apotex for USD 100m, refocuses on orphan drugs
Cumberland Pharmaceuticals (Nasdaq: CPIX) has entered into a definitive agreement to divest its branded commercial pharmaceutical portfolio to Canada-based...
FDA accepts Dogwood Therapeutics' SP16 IND application for chemotherapy-induced pain and neuropathy
Dogwood Therapeutics announced that the US FDA has accepted an Investigational New Drug (IND) application for SP16, an intravenously administered...
Create Medicines' in vivo NK CAR therapy shows early promise in HER2-positive solid tumors
CREATE Medicines, the Cambridge, Massachusetts-based biotech, dosed the first patient in a Phase I/II study of MT-304, an mRNA-LNP-delivered in vivo CAR...
Atrium Therapeutics earns USD 15m milestone from Bristol Myers Squibb CVD collaboration
Atrium Therapeutics (Nasdaq: RNA) has earned a USD 15 million development milestone from Bristol Myers Squibb (NYSE: BMY) under their global cardiovascular...
Novo Nordisk's oral semaglutide shows efficacy in Phase III pediatric type 2 diabetes trial
Novo Nordisk (Copenhagen: NOVO B) reported that oral semaglutide reduced HbA1c by 0.83% versus placebo at 26 weeks in children and adolescents with type 2...
Context Therapeutics puts Nectin-4 × CD3 TCE into first clinical study for triple-negative breast cancer
Context Therapeutics (Nasdaq: CNTX) has registered a first-in-human Phase I clinical trial for CT-202, a Nectin-4 × CD3 bispecific T cell engaging antibody,...
Ferrosa Therapeutics closes USD 3.5m seed round for bispecific anemia inflammation antibody
Ferrosa Therapeutics AG, a Basel, Switzerland-based biotechnology company developing a bispecific antibody for anemia of inflammation, has closed a USD 3.5...
Servier completes USD 2.5b acquisition of Day One Bio for pediatric glioma asset Ojemda
France-based Servier has completed the acquisition of US-based Day One Biopharmaceuticals (Nasdaq: DAWN) via a tender offer at USD 21.50 per share,...
Mozart Therapeutics' potential first-in-class CD8 modulator shows promise in type 1 diabetes
Mozart Therapeutics reported interim Phase Ib results for MTX-101 in adults with Stage 3 type 1 diabetes, with data from five patients presented at the 21st...
AstraZeneca’s surovatamig secures EU orphan drug designation for large B-cell lymphoma
AstraZeneca’s surovatamig received EU orphan drug designation from the European Medicines Agency (EMA) on 20 April 2026 for the treatment of large…
Laboratoires Kol secures EMA Orphan Drug Designation for aganirsen in corneal graft rejection
Laboratoires Kol received orphan drug designation from the European Medicines Agency (EMA) on 20 April 2026 for aganirsen in the prevention of…
Merck and Google Cloud partner on USD 1b agentic AI deployment across R&D and operations
Merck (NYSE: MRK) and Google Cloud announced a multi-year technology collaboration valued at up to USD 1 billion to deploy an agentic…
BioAge Labs' NLRP3 inhibitor shows strong inflammation reduction in obesity with elevated systemic inflammation
BioAge Labs reported Phase I results for BGE-102, an oral small-molecule NLRP3 inhibitor, in participants with obesity and elevated systemic inflammation,...
Roche/Genentech's Enspryng set for approval filings in MOGAD after strong Phase III
Genentech reported that satralizumab (Enspryng) reduced the risk of relapse by 68% compared to placebo in the Phase III METEOROID study in myelin...
The AllSci Brief
Systematic R&D and deal news. Daily.